Published in Clin Pharmacol Ther on August 01, 1981
Value of Technology to Transfer Discharge Information | NCT00101868
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ (2004) 21.39
Drug complications in outpatients. J Gen Intern Med (2000) 5.04
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One (2009) 3.45
Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ (2008) 3.24
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol (2007) 2.97
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. J Gen Intern Med (2008) 2.46
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Electronic prescribing improves medication safety in community-based office practices. J Gen Intern Med (2010) 2.22
The effect of automated alerts on provider ordering behavior in an outpatient setting. PLoS Med (2005) 2.21
Evaluation of Perioperative Medication Errors and Adverse Drug Events. Anesthesiology (2016) 2.05
Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health (2008) 1.95
Weekly active-learning activities in a drug information and literature evaluation course. Am J Pharm Educ (2006) 1.90
Adverse drug reaction and causality assessment scales. Lung India (2011) 1.86
The impact of computerized provider order entry on medication errors in a multispecialty group practice. J Am Med Inform Assoc (2010) 1.85
Women encounter ADRs more often than do men. Eur J Clin Pharmacol (2008) 1.83
Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol (2007) 1.76
Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc (2006) 1.75
Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol (2008) 1.69
Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J (2012) 1.68
Integration of first- and second-year introductory pharmacy practice experiences. Am J Pharm Educ (2009) 1.67
Inappropriate prescribing and adverse drug events in older people. BMC Geriatr (2009) 1.66
Adverse drug reactions in children--a systematic review. PLoS One (2012) 1.65
Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital. Br J Clin Pharmacol (2005) 1.64
Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol (2012) 1.59
The quality of reports on cervical arterial dissection following cervical spinal manipulation. PLoS One (2013) 1.57
Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy (2010) 1.55
Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol (2014) 1.52
Sertraline hepatotoxicity: report of a case and review of the literature. Dig Dis Sci (2008) 1.49
Development of a computerized adverse drug event monitor. Proc Annu Symp Comput Appl Med Care (1991) 1.49
A case of acute renal failure in a patient recently treated with clozapine and a review of previously reported cases. Prim Care Companion CNS Disord (2011) 1.48
Safety aspects of iodinated contrast media related to their physicochemical properties: a pharmacoepidemiology study in two Tuscany hospitals. Eur J Clin Pharmacol (2008) 1.46
Prevalence of commonly prescribed medications potentially contributing to urinary symptoms in a cohort of older patients seeking care for incontinence. BMC Geriatr (2013) 1.46
Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol (2007) 1.46
RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci (2015) 1.45
Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One (2011) 1.45
High serum concentrations of cyclosporin related to administration of tigecycline. Eur J Clin Pharmacol (2008) 1.44
The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. J Am Geriatr Soc (2010) 1.42
Mirtazapine induced nightmares in an adult male. Br J Clin Pharmacol (2008) 1.40
Days lost due to disability of diclofenac-induced adverse drug reactions. Pharm Pract (Granada) (2012) 1.39
Dyslipidemic drugs in metabolic syndrome. Indian J Endocrinol Metab (2013) 1.39
Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ (2002) 1.34
Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol (2010) 1.31
Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc (2011) 1.30
Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract (Granada) (2011) 1.28
Adverse drug reactions: a cohort study in internal medicine units at a university hospital. Eur J Clin Pharmacol (2006) 1.27
Meropenem-induced hypokalemia and metabolic alkalosis. Indian J Pharmacol (2012) 1.26
A review of causal inference for biomedical informatics. J Biomed Inform (2011) 1.25
Clinical experience with intravenous lipid emulsion for drug-induced cardiovascular collapse. J Med Toxicol (2012) 1.25
Evaluating adverse drug event reporting in administrative data from emergency departments: a validation study. BMC Health Serv Res (2013) 1.23
Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J Res Med Sci (2011) 1.22
Association of adverse drug reactions with drug-drug and drug-disease interactions in frail older outpatients. Age Ageing (2010) 1.22
Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol (2010) 1.21
Thrombocytopenia due to rifampicin. Lung India (2012) 1.21
OAE: The Ontology of Adverse Events. J Biomed Semantics (2014) 1.20
Pattern of adverse drug reactions reported by the community pharmacists in Nepal. Pharm Pract (Granada) (2010) 1.20
The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer (2004) 1.19
Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen. Indian J Pharmacol (2010) 1.19
Linezolid-induced black hairy tongue: a case report. J Med Case Rep (2013) 1.19
Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol (2009) 1.18
Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol (2007) 1.18
Transitioning between electronic health records: effects on ambulatory prescribing safety. J Gen Intern Med (2011) 1.16
Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax (2003) 1.15
A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother (2011) 1.14
Programmable infusion pumps in ICUs: an analysis of corresponding adverse drug events. J Gen Intern Med (2008) 1.14
Adverse drug reaction reporting in a pharmacovigilance centre of Nepal. Australas Med J (2012) 1.14
Post-Discharge Adverse Events Among Urban and Rural Patients of an Urban Community Hospital: A Prospective Cohort Study. J Gen Intern Med (2015) 1.13
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Saf (2014) 1.13
Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis (2000) 1.13
Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother (2006) 1.13
Adverse Drug Reaction Reporting Program of the Ontario Medical Association: the first 3 years. Can Med Assoc J (1985) 1.12
Drug-induced uveitis. J Ophthalmic Inflamm Infect (2013) 1.11
ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). Am J Gastroenterol (2014) 1.10
Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol (2007) 1.10
Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol (1999) 1.10
Olanzapine induced neuroleptic malignant syndrome. Indian J Pharmacol (2013) 1.10
A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol (2014) 1.09
Recurrent lymphocytic myocarditis in a young male with ulcerative colitis. Eur J Med Res (2014) 1.08
Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. BMC Med (2013) 1.07
Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient. Indian J Pharmacol (2011) 1.07
Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol (2012) 1.05
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs (2010) 1.05
Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol (2015) 1.04
The case report: a tool for the toxicologist. J Med Toxicol (2009) 1.04
Stevens-Johnson syndrome following use of metronidazole in a dental patient. Indian J Pharmacol (2014) 1.03
Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol (2007) 1.03
Canagliflozin-induced pancreatitis: a rare side effect of a new drug. Ther Clin Risk Manag (2015) 1.02
Development and validation of a risk model for predicting adverse drug reactions in older people during hospital stay: Brighton Adverse Drug Reactions Risk (BADRI) model. PLoS One (2014) 1.02
Pantoprazole-induced acute interstitial nephritis. CMAJ (2012) 1.02
Fixed drug eruption with ornidazole having cross-sensitivity to secnidazole but not to other nitro-imidazole compounds: a case report. Br J Clin Pharmacol (2010) 1.01
An Update on Drug-induced Liver Injury. J Clin Exp Hepatol (2012) 1.01
Computerized detection of adverse drug reactions in the medical intensive care unit. Int J Med Inform (2011) 1.01
Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol (1982) 1.00
Computerized survelliance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol (1998) 1.00
Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS. Case Rep Med (2014) 0.99
Herbal hepatotoxicity: a critical review. Br J Clin Pharmacol (2013) 0.99
Misuse of the Naranjo Adverse Drug Reaction Probability Scale in toxicology. Clin Toxicol (Phila) (2013) 0.99
Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med (1975) 7.60
Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict (1989) 6.58
Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 6.35
Genetic evidence for selective transport of opsin and arrestin by kinesin-II in mammalian photoreceptors. Cell (2000) 4.51
An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol (2000) 3.99
The fermentation process in tea manufacture: Tea tannin and its fermentation products. Biochem J (1939) 3.61
The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet (1995) 3.41
Clinical pharmacokinetics (second of two parts). N Engl J Med (1975) 3.17
Use of benzodiazepines in anxiety disorders. N Engl J Med (1993) 3.12
Drug therapy: drug disposition in old age. N Engl J Med (1982) 3.04
The secondary oxidation of amino-acids by the catechol oxidase of belladonna. Biochem J (1948) 3.01
Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet (2000) 2.94
Midazolam: pharmacology and uses. Anesthesiology (1985) 2.89
Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature (2001) 2.84
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
The respiration and anaerobic fermentation of tea leaf and their relationship to tea fermentation. Biochem J (1940) 2.63
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Clinical pharmacology and therapeutics of benzodiazepines. Can Med Assoc J (1978) 2.40
Intramuscular injection of drugs. N Engl J Med (1976) 2.20
Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18
Nicotine metabolism defect reduces smoking. Nature (1998) 2.17
Diazepam disposition determinants. Clin Pharmacol Ther (1980) 2.16
Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology (1984) 2.14
Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr (2000) 2.11
A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther (1997) 2.06
Treatment of acetaminophen poisoning. Can Med Assoc J (1981) 2.05
Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther (1977) 2.05
Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children. Lancet (1996) 2.04
Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166) Arch Gen Psychiatry (1999) 1.94
Methods for the volumetric estimation of tea tannin in green-leaf and black tea. A new alkaline permanganate method. Biochem J (1940) 1.88
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos (2000) 1.87
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol (1996) 1.86
Binding of drugs to serum albumin (first of two parts). N Engl J Med (1976) 1.85
Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry (1990) 1.84
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol (2000) 1.82
Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol (1989) 1.78
Automated gas chromatography for studies of midazolam pharmacokinetics. Anesthesiology (1981) 1.78
Hepatic abscess and cystic fibrosis. Postgrad Med J (1988) 1.77
Inter- and intrasubject variation in diazepam free fraction. Clin Pharmacol Ther (1979) 1.76
Alcohol intoxication and withdrawal. N Engl J Med (1976) 1.74
Identification of a Mycobacterium tuberculosis gene that enhances mycobacterial survival in macrophages. J Bacteriol (2000) 1.73
Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs. Ann N Y Acad Sci (1971) 1.67
Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol (1978) 1.65
The ambiguity of adverse drug reactions. Eur J Clin Pharmacol (1977) 1.64
Defective kinesin heavy chain behavior in mouse kinesin light chain mutants. J Cell Biol (1999) 1.62
Clinical pharmacokinetics of quinidine. Clin Pharmacokinet (1980) 1.59
Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol (2010) 1.59
Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol (1981) 1.59
Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. N Engl J Med (1970) 1.59
Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther (1970) 1.58
Development of optimal treatment tactics for alcohol withdrawal. I. Assessment and effectiveness of supportive care. J Clin Psychopharmacol (1981) 1.56
Ah receptor in human placenta: stabilization by molybdate and characterization of binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methylcholanthrene, and benzo(a)pyrene. Cancer Res (1987) 1.54
Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs (1974) 1.54
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA (1973) 1.54
Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev (1978) 1.54
Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther (2001) 1.52
Drug therapy. Binding of drugs to serum albumin (second of two parts). N Engl J Med (1976) 1.49
Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand (2003) 1.48
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos (2001) 1.47
Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther (1980) 1.47
Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology (2001) 1.45
The Tourette syndrome diagnostic confidence index: development and clinical associations. Neurology (1999) 1.44
Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther (1998) 1.44
Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J (1977) 1.43
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med (1980) 1.42
Genome-wide association study of Tourette's syndrome. Mol Psychiatry (2012) 1.42
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol (1997) 1.42
Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. J Chromatogr (1978) 1.41
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry (2000) 1.40
Drug transporters in psychopharmacology--are they important? J Clin Psychopharmacol (2000) 1.40
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth (1983) 1.39
Drug therapy. Current status of benzodiazepines. N Engl J Med (1983) 1.39
MAOIs and hypertension. J Clin Psychopharmacol (1992) 1.39
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol (1996) 1.39
Amitriptyline and ethanol: pharmacokinetic and pharmacodynamic interaction. Eur J Clin Pharmacol (1983) 1.38
An application of computers to curriculum review and planning. J Med Educ (1986) 1.38
Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci (1979) 1.37
Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. Cardiology (1984) 1.37
Effect of midazolam infusion and flumazenil administration on epinephrine arrhythmogenicity in dogs anesthetized with halothane. Anesthesiology (1993) 1.37
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry (1990) 1.35
Lorazepam kinetics in the elderly. Clin Pharmacol Ther (1979) 1.35
Pharmacokinetic and clinical implications of quinidine protein binding. J Pharm Sci (1979) 1.34
Diazepam actions and plasma concentrations following ethanol ingestion. Eur J Clin Pharmacol (1977) 1.33
Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. J Clin Pharmacol (1978) 1.33
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr (2001) 1.32
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther (1999) 1.32
Mother-to-infant transmission of hepatitis C virus. Hepatology (2001) 1.32
Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet (1981) 1.31
Measurement issues in postpartum depression part 1: anxiety as a feature of postpartum depression. Arch Womens Ment Health (2003) 1.30
Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther (1978) 1.29
Clinical implications of benzodiazepine pharmacokinetics. Am J Psychiatry (1977) 1.29
Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther (1981) 1.29
Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology (2001) 1.29
Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal. J Stud Alcohol (1977) 1.28
Intramuscular injection-site complications. JAMA (1978) 1.28